NPPA Fixes Retail Prices of 42 Formulations Including Amoxycillin, Dapagliflozin, Cefixime
New Delhi: Through a recent notification, the National Pharmaceutical Pricing Authority (NPPA), under the Ministry of Chemicals and Fertilizers, has fixed the retail price of 42 formulations under the Drugs (Price Control) Order, 2013.
The authority has fixed the retail prices based on a decision at the 136th Authority meeting dated 28.8.2025.
The list includes Amoxycillin and Potassium Clavulanate Oral Suspension manufactured and marketed by Copmed Pharmaceuticals/Zydus Healthcare; Bilastine and Montelukast Tablets manufactured and marketed by Skymap Pharmaceuticals/German Remedies Pharmaceuticals; Cefixime and Ofloxacin (SR) Tablets manufactured and marketed by Malik Lifesciences/Alkem Laboratories; Cilnidipine and Telmisartan Tablets manufactured and marketed by Pure and Cure Healthcare/Lupin; and Dapagliflozin, Glimepiride and Metformin Hydrochloride (Extended Release) Tablets manufactured and marketed by Akums Drugs and Pharmaceuticals/Dr. Reddy’s Laboratories and others.
In exercise of the powers conferred by paragraphs 5, 11 and 15 of the Drugs (Prices Control) Order, 2013, read with S.O. 1394(E) dated the 30th May, 2013 and S.O. 5249(E) dated 11th November, 2022 issued by the Government of India in the Ministry of Chemicals and Fertilizers, the National Pharmaceutical Pricing Authority (hereinafter referred as NPPA) has fixed, the price as specified in column (6) of the table herein below as the retail price, exclusive of Goods and Services Tax, if any, in relation to the formulation specified in the corresponding entry in column (2) of the said Table with the strength, unit and name of manufacturer & marketing company, as specified in the corresponding entries in columns (3), (4) and (5) thereof;
Sl. No. | Medicines | Strength | Unit | Manufacturer & Marketing Company | Retail Price (Rs.) |
(1) | (2) | (3) | (4) | (5) | (6) |
1 | Amoxycillin & Potassium Clavulanate Oral suspension | Each 5 ml of constituted suspension contains: Amoxycillin Trihydrate IP Equivalent to Amoxycillin 400 mg Potassium Clavulanate Diluted IP Equivalent to Clavulanic Acid 57 mg | 1 ml | M/s Copmed Pharmaceuticals Pvt. Ltd./ M/s Zydus Healthcare Ltd. | 4.69 |
2 | Amoxycillin & Potassium Clavulanate Oral suspension | Each ml of the reconstituted suspension contains: Amoxycillin Trihydrate IP equivalent to Amoxycillin 80 mg Potassium Clavulanate Diluted IP equivalent to Clavulanic Acid 11.4 mg | 1 ml | M/s Malik LifeSciences Pvt. Ltd./ M/s Aurobindo Pharma Ltd. | 7.14 |
3 | Bilastine & Montelukast Tablets | Each film coated tablet contains: Bilastine IP 20 mg Montelukast Sodium IP equivalent to Montelukast 10 mg | 1 Tablet | M/s Skymap Pharmaceuticals Pvt. Ltd./ M/s German Remedies Pharmaceuticals Pvt. Ltd. | 13.97 |
4 | Bisoprolol Fumarate & Amlodipine tablets | Each film coated tablet contains: Bisoprolol Fumarate IP 5 mg Amlodipine Besylate equivalent to Amlodipine IP 5 mg | 1 Tablet | M/s Swiss Garnier Life sciences/ M/s Cadila Pharmaceuticals Ltd. | 8.72 |
5 | Calcium & Vitamin D3 tablets | Each film coated tablet contains: Calcium Citrate Malate IP eq. to Elemental Calcium 250 mg Vitamin D3 IP 1000 IU | 1 Tablet | M/s Pure & Cure Healthcare Pvt. Ltd./ M/s Torrent Pharmaceuticals Ltd. | 12.09 |
6 | Cefixime & Ofloxacin (SR) Tablets | Each film coated Sustained Release tablet contains: Cefixime IP as Trihydrate Eq. to Anhydrous Cefixime 400mg Ofloxacin IP 400mg | 1 Tablet | M/s Malik Lifesciences Pvt. Ltd./ M/s Alkem Laboratories Ltd. | 30.79 |
7 | Cefixime & Ofloxacin oral suspension | Each 5ml reconstituted suspension contains: Cefixime IP as Trihydrate Eq. to Anhydrous Cefixime 50mg Ofloxacin IP 50mg | 1 ml | M/s Innova Captab Ltd. /M/s FDC Ltd. | 2.00 |
8 | Cefixime Dispersible Tablets | Each Uncoated Dispersible Tablet Contains: Cefixime IP Eq. to Anhydrous Cefixime 100 mg | 1 Tablet | M/s Skymap Pharmaceuticals Pvt. Ltd./ M/s German Remedies Pharmaceuticals Pvt. Ltd. | 7.56 |
Sl. No. | Medicines | Strength | Unit | Manufacturer & Marketing Company | Retail Price (Rs.) |
9 | Cefpodoxime & Potassium Clavulanate Tablets | Each film coated tablet contains: Cefpodoxime Proxetil IP eq. to Cefpodoxime 200 mg Potassium Clavulanate Diluted IP eq. to Clavulanic Acid 125 mg | 1 Tablet | M/s Malik Lifesciences Pvt. Ltd./ M/s Akumentis Healthcare Ltd. | 30.72 |
10 | Cholecalciferol (Vitamin D3) Oral Solution | Each 5 ml contains: Cholecalciferol IP (In Nano Droplet Form) 60,000 IU | 1 ml | M/s Ravenbhel Healthcare Pvt. Ltd./ M/s Zydus Healthcare Ltd. | 15.17 |
11 | Cilnidipine & Telmisartan Tablets | Each Film Coated Tablet Contains: Cilnidipine IP 10 mg Telmisartan IP 80 mg | 1 Tablet | M/s Pure & Cure Healthcare Pvt. Ltd./ M/s Lupin Ltd. | 17.37 |
12 | Dapagliflozin, Glimepiride & Metformin Hydrochloride (Extended Release) Tablets | Each film coated bilayered tablet contains: Dapagliflozin Propanediol USP Eq. to Dapagliflozin 10mg Glimepiride IP 1 mg Metformin Hydrochloride IP 500mg (As Extended Release Form) | 1 Tablet | M/s Akums Drugs & Pharmaceuticals Ltd./ M/s Dr. p’s Laboratories Ltd. | 11.02 |
13 | Dapagliflozin, Glimepiride & Metformin Hydrochloride (Extended Release) Tablets | Each film coated bilayered tablet contains: Dapagliflozin Propanediol USP Eq. to Dapagliflozin 10mg Glimepiride IP 2 mg Metformin Hydrochloride IP 500mg (As Extended Release Form) | 1 Tablet | M/s Akums Drugs & Pharmaceuticals Ltd./ M/s Dr. Reddy’s Laboratories Ltd. | 11.81 |
14 | Empagliflozin & Metformin Hydrochloride Tablets | Each film-coated tablet contains: Empagliflozin 12.5 mg Metformin Hydrochloride IP 500 mg | 1 Tablet | M/s Windlas Biotech Ltd./ M/s Systopic Laboratories Pvt Ltd | 18.10 |
15 | Empagliflozin, Linagliptin & Metformin Hydrochloride (Extended Release) Tablets | Each film coated bilayer tablet contains:Linagliptin 5 mg Empagliflozin 25 mg Metformin Hydrochloride (As Extended Release) IP 1000 mg | 1 Tablet | M/s Exemed Pharmaceuticals / M/s Natco Pharma Ltd. | 25.00 |
16 | Empagliflozin, Sitagliptin & Metformin Hydrochloride (Extended Release) Tablets | Each film coated bilayer tablet contains: Empagliflozin 10 mg Metformin Hydrochloride (As Extended Release) IP 1000mg Sitagliptin Phosphate Monohydrate IP Equivalent to Sitagliptin 100 mg | 1 Tablet | M/s Exemed Pharmaceuticals / M/s Cadila Pharmaceuticals Ltd. | 31.75 |
17 | Empagliflozin, Sitagliptin & Metformin Hydrochloride (Extended Release) Tablets | Each film coated bilayer tablet contains: Sitagliptin Phosphate Monohydrate IP Equivalent to Sitagliptin 100 mg Metformin Hydrochloride (As Extended Release) IP 1000mg Empagliflozin 25 mg | 1 Tablet | M/s Exemed Pharmaceuticals / M/s Cadila Pharmaceuticals Ltd. | 35.29 |
18 | Empagliflozin, Sitagliptin & Metformin Hydrochloride | Each film coated bilayer tablet contains: Empagliflozin 10 mg Metformin Hydrochloride (As Extended Release) IP 1000 mg | 1 Tablet | M/s Exemed Pharmaceuticals/ M/s MSN Laboratories Pvt. Ltd. | 22.90 |
Sl. No. | Medicines | Strength | Unit | Manufacturer & Marketing Company | Retail Price (Rs.) |
(Extended Release) Tablets | Sitagliptin Phosphate Monohydrate IP Equivalent to Sitagliptin 100 mg | ||||
19 | Empagliflozin, Sitagliptin & Metformin Hydrochloride (Extended Release) Tablets | Each film coated bilayer tablet contains: Sitagliptin Phosphate Monohydrate IP Equivalent to Sitagliptin 100 mg Metformin Hydrochloride (As Extended Release) IP 1000mg Empagliflozin 25 mg | 1 Tablet | M/s Exemed Pharmaceuticals/ M/s MSN Laboratories Pvt. Ltd. | 23.90 |
20 | Indomethacin & Paracetamol Capsules | Each hard gelatin capsule contains: Indomethacin IP (enteric coated) 25mg Paracetamol IP 325 mg | 1 Capsule | M/s Windlas Biotech Ltd./ M/s Micro Labs Ltd. | 6.22 |
21 | Meropenem & Sulbactam for Injection | Each vial contains: Meropenem Trihydrate IP Eq. to Anhydrous Meropenem 1000 mg Sodium (as Sodium Carbonate IP) 90.2 mg Sulbactam Sodium IP equivalent to Sulbactam 500 mg | 1 Vial | M/s GMH Organics / M/s Zydus Healthcare Ltd. | 1938.59 |
22 | Mycophenolate Mofetil Tablets | Each film coated tablet contains: Mycophenolate Mofetil IP 750 mg | 1 Tablet | M/s Ipca Laboratories Ltd. | 131.58 |
23 | Ofloxacin & Metronidazole Oral Suspension | Each 5ml contains: Ofloxacin IP 100mg Metronidazole Benzoate IP Eq. to Metronidazole 200mg | 1 ml | M/s Aryatech Pharma Pvt. Ltd./ M/s Alkem Laboratories Ltd. | 1.04 |
24 | Ofloxacin & Metronidazole Suspension | Each 5 ml contains: Ofloxacin IP 100 mg Metronidazole Benzoate IP Equivalent to Metronidazole 200 mg | 1 ml | M/s Hema Laboratories Pvt. Ltd./ M/s Abbott Healthcare Pvt. Ltd. | 1.04 |
25 | Olmesartan Medoxomil, Amlodipine & Hydrochlorothiazide Tablets | Each film coated tablet contains: Olmesartan Medoxomil IP 40 mg Amlodipine Besilate IP Eq. to Amlodipine 5mg Hydrochlorothiazide IP 12.5mg | 1 Tablet | M/s Windlas Biotech Ltd./ M/s Alkem Laboratories Ltd. | 20.98 |
26 | Olmesartan Medoxomil, Amlodipine & Hydrochlorothiazide Tablets | Each film coated tablet contains: Olmesartan Medoxomil IP 20mg Amlodipine Besilate IP Eq. to Amlodipine 5mg Hydrochlorothiazide IP 12.5mg | 1 Tablet | M/s Windlas Biotech Ltd./ M/s Alkem Laboratories Ltd. | 15.82 |
27 | Paracetamol Infusion | Each ml contains: Paracetamol IP 10 mg | 1 ml | M/s Appasamy Ocular Devices Pvt. Ltd./ M/s Tyykem Pvt. Ltd. | 3.41 |
28 | Paracetamol, Phenylephrine Hydrochloride, Caffeine & Diphenhydramine Hydrochloride Tablets | Each film coated tablet contains: Paracetamol IP 500 mg Phenylephrine Hydrochloride IP 5 mg Caffeine (anhydrous) IP 30 mg Diphenhydramine Hydrochloride IP 25 mg | 1 Tablet | M/s Prosperity Drugs Pvt. Ltd./ M/s Intas Pharmaceuticals Ltd. | 4.49 |
29 | Povidone-Iodine & Metronidazole Ointment | Povidone-Iodine IP 5 % w/w (Available Iodine 0.5% w/w) Metronidazole IP 1% w/w | 1 gm | M/s Nanz Med Science Pharma (P) Ltd./ M/s Mankind Prime Labs Pvt. Ltd. | 3.77 |
Sl. No. | Medicines | Strength | Unit | Manufacturer & Marketing Company | Retail Price (Rs.) |
30 | Ramipril & Extended Release Metoprolol Succinate Tablets | Each film coated bilayered tablet contains: Ramipril IP 5 mg Metoprolol Succinate IP 47.5 mg eq. to Metoprolol Tartrate 50 mg (as Extended Release form) | 1 Tablet | M/s Akums Drugs & Pharmaceuticals Ltd./M/s Dr. Reddy’s Laboratories Ltd. | 25.78 |
31 | Rosuvastatin, Aspirin & Clopidogrel Capsules | Each hard gelatin capsule contains: Rosuvastatin Calcium IP Equivalent to Rosuvastatin 10 mg (As granules) Aspirin IP 75 mg (As enteric coated tablets) Clopidogrel Bisulphate IP Equivalent to Clopidogrel 75 mg (as two film coated tablets) | 1 Capsule | M/s Windlas Biotech Ltd./ M/s Merck Specialities Pvt Ltd. | 15.61 |
32 | Rosuvastatin, Aspirin & Clopidogrel Capsules | Each hard gelatin capsule contains: Rosuvastatin Calcium IP equivalent to Rosuvastatin 20 mg (As granules) Aspirin IP 75 mg (As enteric coated tablets) Clopidogrel Bisulphate IP Equivalent to Clopidogrel 75 mg (as two film coated tablets) | 1 Capsule | M/s Windlas Biotech Ltd./ M/s Merck Specialities Pvt Ltd. | 22.76 |
33 | Sitagliptin, Glimepiride & Metformin Hydrochloride Tablets | Each film coated tablet contains: Sitagliptin Phosphate Monohydrate IP Equivalent to Sitagliptin 50 mg Metformin Hydrochloride IP 500 mg Glimepiride IP 1 mg | 1 Tablet | M/s Exemed Pharmaceuticals/ M/s Corona Remedies Pvt. Ltd. | 13.27 |
34 | Sitagliptin, Glimepiride & Metformin Hydrochloride Tablets | Each film coated tablet contains: Sitagliptin Phosphate Monohydrate IP equivalent to Sitagliptin 50 mg Glimepiride IP 2 mg Metformin Hydrochloride IP 500 mg | 1 Tablet | M/s Exemed Pharmaceuticals/ M/s Corona Remedies Pvt. Ltd. | 14.95 |
35 | Telmisartan & Amlodipine Tablets | Each film coated tablet contains: Telmisartan IP 80 mg Amlodipine Besilate IP Eq. to Amlodipine 5 mg | 1 Tablet | M/s Lifecare Formulations Pvt. Ltd. / M/s Primus Remedies Pvt. Ltd. | 20.15 |
36 | Telmisartan & Amlodipine Tablets | Each uncoated Tablet contains: Telmisartan IP 80 mg Amlodipine Besilate IP eq. to Amlodipine 5 mg | 1 Tablet | M/s Swiss Garnier Life Sciences/ M/s Workcell Solutions Pvt. Ltd. | 16.00 |
37 | Voglibose & Metformin HCl (SR) Tablets | Each uncoated bilayered tablet contains: Voglibose IP 0.3 mg Metformin Hydrochloride IP 500 mg (as sustained release form) | 1 Tablet | M/s Swiss Garnier Life Sciences/ M/s Workcell Solutions Pvt. Ltd. | 11.61 |
38 | Cefixime & Ofloxacin oral suspension | Each 5 ml reconstituted suspension contains: Cefixime Trihydrate IP equivalent to Cefixime anhydrous 50 mg Ofloxacin IP 50 mg | 1 ml | M/s Alkem Healthscience (A unit of Alkem Laboratories Ltd.) / M/s Alkem Laboratories Ltd. | 1.93 |
Sl. No. | Medicines | Strength | Unit | Manufacturer & Marketing Company | Retail Price (Rs.) |
39 | Ceftriaxone and Tazobactam injection | Each vial contains: Ceftriaxone Sodium IP equivalent to anhydrous Ceftriaxone 1000 mg Tazobactam Sodium IP equivalent to anhydrous Tazobactam 125mg | 1 vial | M/s East African (India) Overseas / M/s FDC Limited | 199.26 |
40 | Amlodipine & Bisoprolol Fumarate Tablets | Each film coated tablet contains: Amlodipine Besylate IP eq. to Amlodipine 2.5 mg Bisoprolol Fumarate IP 5 mg | 1 Tablet | M/s Exemed Pharmaceuticals/ M/s Torrent Pharmaceuticals Ltd. | 9.47 |
41 | Amlodipine & Bisoprolol Fumarate Tablets | Each film coated tablet contains: Amlodipine Besylate IP eq. to Amlodipine 2.5 mg Bisoprolol Fumarate IP 2.5 mg | 1 Tablet | M/s Exemed Pharmaceuticals/M/s Torrent Pharmaceuticals Ltd | 7.39 |
42 | Clarithromycin Extended Release Tablets | Each Extended Release film coated tablet contains: Clarithromycin IP 1000 mg | 1 Tablet | M/s Abbott Healthcare Pvt. Ltd. | 71.71 |
The notification further added:
(a) The manufacturer of above-mentioned formulations i.e., “new drug” under paragraph 2(1)(u) of the DPCO, 2013 shall fix the retail price as specified in column (6) of the table hereinabove.
(b) The manufacturer may add Goods and Services Tax only if they have paid actually or it is payable to the Government on the retail price mentioned in column (6) of the above said table.
(c) The retail price for a pack of the aforesaid formulation shall be arrived at by the concerned manufacturer in accordance with the retail price specified in column (6) of the above table as per provisions contained in paragraph 11 of the DPCO, 2013. The manufacturer shall issue a price list in Form–V from date of Notification as per paragraph 24 of the DPCO, 2013 to NPPA through IPDMS and submit a copy to State Drug Controller and dealers.
(d) As per para 24(4) of DPCO 2013, every retailer and dealer shall display price list and the supplementary price list, if any, as furnished by the manufacturer, on a conspicuous part of the premises where he carries on business in a manner so as to be easily accessible to any person wishing to consult the same.
(e) The above mentioned retail price is applicable only to the individual manufacturer / marketer as mentioned above i.e. who have applied for the same by submitting Form-I for price fixation / revision as stipulated under DPCO, 2013 and subject to fulfilment of all the applicable statutory requirements as laid down by the Govt. under relevant statutes/ rules, including manufacturing license permission from the Competent Authority i.e. the Central/State Licensing Authority, as may be applicable, by the concerned manufacturer/marketing companies.
(f) In case the retail price of any of the aforesaid formulations is not complied with, as per instant price notification and notes specified hereinabove, then the concerned manufacturer/marketing company shall be liable to deposit the overcharged amount along with the interest thereon under the provisions of the DPCO, 2013 read with the Essential Commodities Act, 1955.
(g) Consequent to the fixation of retail price of such formulation as specified in column (2) of the above table with the strength and name of Manufacturer & Marketing Companies specified in the corresponding entries in Column (3) & (5) thereof, the price order(s) fixing the retail price of the formulation with specified strength for that Manufacturer and Marketing Companies as specified in corresponding entries in Column (2), (3) and (5) thereof, if any, issued prior to this notification, stand(s) superseded.
To view the official notice, click the link below:
Susmita Roy, B pharm, M pharm Pharmacology, graduated from Gurunanak Institute of Pharmaceutical Science and Technology with a bachelor's degree in Pharmacy. She is currently working as an assistant professor at Haldia Institute of Pharmacy in West Bengal. She has been part of Medical Dialogues since March 2021.
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.